The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
ADC Therapeutics, Inc. Common H0036K147 5,309 218,027 SH   SOLE   218,027 0 0
Cullinan Management, Inc. Common 230031106 203,783 7,913,887 SH   SOLE   7,913,887 0 0
Epizyme, Inc. Common 29428V104 19,375 2,331,534 SH   SOLE   2,331,534 0 0
G1 Therapeutics, Inc. Common 3621LQ109 17,833 812,794 SH   SOLE   812,794 0 0
Harpoon Therapeutics, Inc. Common 41358P106 44,338 3,196,707 SH   SOLE   3,196,707 0 0
iTeos Therapeutics, Inc. Common 46565G104 59,985 2,338,581 SH   SOLE   2,338,581 0 0
MEI Pharma, Inc. Common 552798202 28,893 10,137,859 SH   SOLE   10,137,859 0 0
Merus N.V. Common N5749R100 14,768 700,879 SH   SOLE   700,879 0 0
Oncorus, Inc. Common 68236R103 32,803 2,377,031 SH   SOLE   2,377,031 0 0
Repare Therapeutics, Inc. Common 760273102 52,260 1,676,087 SH   SOLE   1,676,087 0 0
TCR2 Therapeutics, Inc. Common 87808K106 55,318 3,370,982 SH   SOLE   3,370,982 0 0
Turning Point Therapeutics, Inc. Common 90041T108 21,002 269,186 SH   SOLE   269,186 0 0
Werewolf Therapeutics, Inc. Common 95075A107 41,647 2,388,011 SH   SOLE   2,388,011 0 0
YmAbs Therapeutics, Inc. Common 984241109 11,400 337,291 SH   SOLE   337,291 0 0